Alnylam Pharmaceuticals
ALNY
ALNY
475 hedge funds and large institutions have $22.5B invested in Alnylam Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 163 increasing their positions, 155 reducing their positions, and 54 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
1.12% less ownership
Funds ownership: 96.32% → 95.21% (-1.1%)
6% less capital invested
Capital invested by funds: $24B → $22.5B (-$1.43B)
26% less call options, than puts
Call options by funds: $119M | Put options by funds: $162M
Holders
475
Holding in Top 10
6
Calls
$119M
Puts
$162M
Top Buyers
| 1 | +$129M | |
| 2 | +$129M | |
| 3 | +$83.7M | |
| 4 |
Bank of New York Mellon
New York
|
+$43.9M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$41M |
Top Sellers
| 1 | -$162M | |
| 2 | -$134M | |
| 3 | -$83M | |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$50.4M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$49M |